JP2013502221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013502221A5 JP2013502221A5 JP2012525677A JP2012525677A JP2013502221A5 JP 2013502221 A5 JP2013502221 A5 JP 2013502221A5 JP 2012525677 A JP2012525677 A JP 2012525677A JP 2012525677 A JP2012525677 A JP 2012525677A JP 2013502221 A5 JP2013502221 A5 JP 2013502221A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- adenovirus
- protein
- modified
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 claims description 287
- 201000004792 malaria Diseases 0.000 claims description 152
- 150000007523 nucleic acids Chemical group 0.000 claims description 152
- 101000666856 Homo sapiens Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 claims description 136
- 102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 claims description 136
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 129
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 117
- 108090000623 proteins and genes Proteins 0.000 claims description 114
- 244000045947 parasite Species 0.000 claims description 111
- 102000004169 proteins and genes Human genes 0.000 claims description 106
- 210000003046 sporozoite Anatomy 0.000 claims description 83
- 229960005486 vaccine Drugs 0.000 claims description 63
- 239000013598 vector Substances 0.000 claims description 60
- 108090000565 Capsid Proteins Proteins 0.000 claims description 55
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 52
- 239000000835 fiber Substances 0.000 claims description 48
- 241000223960 Plasmodium falciparum Species 0.000 claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims description 45
- 208000015181 infectious disease Diseases 0.000 claims description 44
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 43
- 239000002671 adjuvant Substances 0.000 claims description 38
- 101710132601 Capsid protein Proteins 0.000 claims description 35
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 25
- 230000028996 humoral immune response Effects 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 19
- 230000000890 antigenic effect Effects 0.000 claims description 18
- 230000003472 neutralizing effect Effects 0.000 claims description 18
- 101710145505 Fiber protein Proteins 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 16
- 230000002163 immunogen Effects 0.000 claims description 15
- 241000224016 Plasmodium Species 0.000 claims description 14
- 108020004705 Codon Proteins 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 230000024932 T cell mediated immunity Effects 0.000 claims description 8
- 108700005482 Protozoan circumsporozoite Proteins 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 3
- 101710198223 Capsid fiber protein Proteins 0.000 claims description 2
- 101710143509 Pre-histone-like nucleoprotein Proteins 0.000 claims 8
- KQPKMEYBZUPZGK-UHFFFAOYSA-N 4-[(4-azido-2-nitroanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CC1=NC=C(CO)C(CNC=2C(=CC(=CC=2)N=[N+]=[N-])[N+]([O-])=O)=C1O KQPKMEYBZUPZGK-UHFFFAOYSA-N 0.000 claims 6
- 101001111984 Homo sapiens N-acylneuraminate-9-phosphatase Proteins 0.000 claims 6
- 102100023906 N-acylneuraminate-9-phosphatase Human genes 0.000 claims 6
- 101710117490 Circumsporozoite protein Proteins 0.000 claims 4
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 description 154
- 102000039446 nucleic acids Human genes 0.000 description 144
- 108020004707 nucleic acids Proteins 0.000 description 144
- 101100082057 Mus musculus Aldh18a1 gene Proteins 0.000 description 116
- 235000018102 proteins Nutrition 0.000 description 98
- 235000001014 amino acid Nutrition 0.000 description 78
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 48
- 241000699670 Mus sp. Species 0.000 description 45
- 108020004414 DNA Proteins 0.000 description 36
- 239000000203 mixture Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 34
- 239000013600 plasmid vector Substances 0.000 description 34
- 241001529936 Murinae Species 0.000 description 33
- 230000003053 immunization Effects 0.000 description 31
- 238000002649 immunization Methods 0.000 description 29
- 230000036039 immunity Effects 0.000 description 28
- 239000012634 fragment Substances 0.000 description 26
- 238000003780 insertion Methods 0.000 description 26
- 230000037431 insertion Effects 0.000 description 26
- 108090000765 processed proteins & peptides Chemical group 0.000 description 23
- 101710094396 Hexon protein Proteins 0.000 description 22
- 210000002845 virion Anatomy 0.000 description 21
- 239000000427 antigen Substances 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 210000000234 capsid Anatomy 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 108700019146 Transgenes Proteins 0.000 description 18
- 230000028993 immune response Effects 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000009261 transgenic effect Effects 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 16
- 239000002245 particle Substances 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 12
- 230000003263 anti-adenoviral effect Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 239000013605 shuttle vector Substances 0.000 description 11
- 230000005867 T cell response Effects 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 230000021633 leukocyte mediated immunity Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000012286 ELISA Assay Methods 0.000 description 8
- 241001135569 Human adenovirus 5 Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 229940021704 adenovirus vaccine Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229940124735 malaria vaccine Drugs 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000013022 formulation composition Substances 0.000 description 6
- 230000004727 humoral immunity Effects 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000003252 repetitive effect Effects 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 208000002109 Argyria Diseases 0.000 description 5
- 108010035601 Coxsackie and Adenovirus Receptor Like Membrane Protein Proteins 0.000 description 5
- 102000008198 Coxsackie and Adenovirus Receptor Like Membrane Protein Human genes 0.000 description 5
- 108010042653 IgA receptor Proteins 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 241000223830 Plasmodium yoelii Species 0.000 description 5
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000008348 humoral response Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 4
- 238000001061 Dunnett's test Methods 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 101710152205 Sporozoite antigen Proteins 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 4
- 230000005937 nuclear translocation Effects 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000003146 transient transfection Methods 0.000 description 4
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 3
- 208000002476 Falciparum Malaria Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000224024 Plasmodium chabaudi Species 0.000 description 3
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000078 anti-malarial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 230000000925 erythroid effect Effects 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000003936 merozoite Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 108020004418 ribosomal RNA Proteins 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- TWLQEIBUXHHZPI-UPPQRMANSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]p Chemical group NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2[C@@H](CCC2)C(O)=O)CCC1 TWLQEIBUXHHZPI-UPPQRMANSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 101710203310 Apical membrane antigen 1 Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100027221 CD81 antigen Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100036411 Dermatopontin Human genes 0.000 description 2
- 101710088341 Dermatopontin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- -1 PfEMP1 Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000012722 SDS sample buffer Substances 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 101710097904 Serine-rich antigen Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710109576 Terminal protein Proteins 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 108020001775 protein parts Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical class CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical group CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- AXXCUABIFZPKPM-BQBZGAKWSA-N Asp-Arg-Gly Chemical group [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O AXXCUABIFZPKPM-BQBZGAKWSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100021833 Mesencephalic astrocyte-derived neurotrophic factor Human genes 0.000 description 1
- 101710155665 Mesencephalic astrocyte-derived neurotrophic factor Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000701168 Murine adenovirus 1 Species 0.000 description 1
- 101000819572 Mus musculus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000009182 Parasitemia Diseases 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 101000726057 Plasmodium falciparum Circumsporozoite protein Proteins 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 241000223801 Plasmodium knowlesi Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 108010084938 adenovirus receptor Proteins 0.000 description 1
- 230000025845 adhesion to host Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 102000055772 human CD81 Human genes 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2009/054212 | 2009-08-18 | ||
| PCT/US2009/054212 WO2011022002A1 (en) | 2009-08-18 | 2009-08-18 | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
| PCT/US2010/045952 WO2011022522A1 (en) | 2009-08-18 | 2010-08-18 | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016041230A Division JP6293181B2 (ja) | 2009-08-18 | 2016-03-03 | 免疫原性マラリア原虫周辺スポロゾイトタンパク質エピトープによる組換えアデノウイルスの改変 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013502221A JP2013502221A (ja) | 2013-01-24 |
| JP2013502221A5 true JP2013502221A5 (https=) | 2015-07-30 |
| JP5947719B2 JP5947719B2 (ja) | 2016-07-06 |
Family
ID=43607237
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012525677A Expired - Fee Related JP5947719B2 (ja) | 2009-08-18 | 2010-08-18 | 免疫原性マラリア原虫周辺スポロゾイトタンパク質エピトープによる組換えアデノウイルスの改変 |
| JP2016041230A Expired - Fee Related JP6293181B2 (ja) | 2009-08-18 | 2016-03-03 | 免疫原性マラリア原虫周辺スポロゾイトタンパク質エピトープによる組換えアデノウイルスの改変 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016041230A Expired - Fee Related JP6293181B2 (ja) | 2009-08-18 | 2016-03-03 | 免疫原性マラリア原虫周辺スポロゾイトタンパク質エピトープによる組換えアデノウイルスの改変 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170348405A1 (https=) |
| EP (2) | EP2467157A4 (https=) |
| JP (2) | JP5947719B2 (https=) |
| KR (1) | KR20120094469A (https=) |
| CN (2) | CN103025349B (https=) |
| BR (1) | BR112012003808A2 (https=) |
| CA (1) | CA2769415A1 (https=) |
| IL (1) | IL217709A (https=) |
| MX (1) | MX339830B (https=) |
| NZ (1) | NZ598703A (https=) |
| PH (1) | PH12012500164A1 (https=) |
| RU (1) | RU2585228C2 (https=) |
| SG (2) | SG178476A1 (https=) |
| UA (1) | UA108081C2 (https=) |
| WO (2) | WO2011022002A1 (https=) |
| ZA (1) | ZA201201286B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012154199A1 (en) | 2010-10-18 | 2012-11-15 | The Government Of The United States, As Represented By The Secretary Of The Army | Soluble recombinant plasmodium falciparum circumsporozoite protein |
| US20120244178A1 (en) * | 2011-03-25 | 2012-09-27 | Denise Doolan | Plasmodium falciparum antigens |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| SG10201709917VA (en) * | 2013-06-03 | 2017-12-28 | Vlp Therapeutics Llc | Malaria vaccine |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| US9968665B2 (en) * | 2015-09-16 | 2018-05-15 | Artificial Cell Technologies, Inc. | Anti-malaria compositions and methods |
| LT3405582T (lt) * | 2016-01-21 | 2020-12-10 | Janssen Vaccines & Prevention B.V. | Patobulinta vakciną nuo maliarijos adenoviruso, koduojančio ir eksponuojančio maliarijos antigeną, pagrindu |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| CN107841513B (zh) * | 2016-09-18 | 2023-04-14 | 中国科学院上海巴斯德研究所 | 基于M2e表位的广谱型流感疫苗 |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| CN108192876A (zh) * | 2017-12-07 | 2018-06-22 | 东莞市第八人民医院 | 一种人3型腺病毒衣壳蛋白同时展示ca16双中和抗原表位疫苗候选株的制备方法和应用 |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| WO2020221451A1 (en) * | 2019-04-30 | 2020-11-05 | Humabs Biomed Sa | Antibodies binding to plasmodium circumsporozoite protein and uses thereof |
| CN110687289B (zh) * | 2019-10-17 | 2023-04-18 | 中国人民解放军陆军军医大学 | Fgl2蛋白作为疟疾感染标志物的应用 |
| GB201915905D0 (en) * | 2019-11-01 | 2019-12-18 | Spybiotech Ltd | Viruses with modified capsid proteins |
| JP2021178021A (ja) * | 2020-05-14 | 2021-11-18 | 株式会社三洋物産 | 遊技機 |
| US20240240203A1 (en) * | 2021-05-04 | 2024-07-18 | SpyBiotech Limited | Adenoviral vectors and vaccines thereof |
| CA3233100A1 (en) * | 2021-09-23 | 2023-03-30 | Sagittarius Bio, Inc. | Adenoviruses and methods for using adenoviruses |
| CN120944926B (zh) * | 2025-10-15 | 2026-01-30 | 华中科技大学同济医学院附属同济医院 | 衣壳表面展示超大片段抗原的重组腺病毒、构建方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6066623A (en) * | 1993-11-23 | 2000-05-23 | The United States Of America As Represented By The Secretary Of The Navy | Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines |
| EP1434859A2 (en) * | 2001-07-25 | 2004-07-07 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| AU2003285932A1 (en) * | 2002-10-23 | 2004-05-13 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
| NZ539813A (en) * | 2002-12-17 | 2008-04-30 | Crucell Holland Bv | A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6 |
| JP2007503843A (ja) * | 2003-05-14 | 2007-03-01 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | アデノウイルス親和性の拡大 |
| JP2005287309A (ja) * | 2004-03-31 | 2005-10-20 | Dnavec Research Inc | 遺伝子導入を増強するための薬剤および方法 |
| DE602005025512D1 (de) * | 2004-10-13 | 2011-02-03 | Crucell Holland Bv | Verbesserte adenovirusvektoren und deren verwendung |
| BRPI0615400A2 (pt) * | 2005-08-31 | 2011-05-17 | Genvec Inc | vacinas para malária baseadas em vetor adenoviral |
| US20100272753A1 (en) * | 2006-10-26 | 2010-10-28 | The Johns Hopkins University | Recombinant Adenovirus Vaccines |
-
2009
- 2009-08-18 WO PCT/US2009/054212 patent/WO2011022002A1/en not_active Ceased
-
2010
- 2010-08-18 RU RU2012110255/10A patent/RU2585228C2/ru not_active IP Right Cessation
- 2010-08-18 CN CN201080047059.6A patent/CN103025349B/zh not_active Expired - Fee Related
- 2010-08-18 KR KR1020127006889A patent/KR20120094469A/ko not_active Ceased
- 2010-08-18 EP EP10810576.8A patent/EP2467157A4/en not_active Withdrawn
- 2010-08-18 SG SG2012011144A patent/SG178476A1/en unknown
- 2010-08-18 EP EP18168155.2A patent/EP3412306A3/en not_active Withdrawn
- 2010-08-18 BR BR112012003808A patent/BR112012003808A2/pt not_active IP Right Cessation
- 2010-08-18 NZ NZ598703A patent/NZ598703A/en not_active IP Right Cessation
- 2010-08-18 UA UAA201203125A patent/UA108081C2/ru unknown
- 2010-08-18 MX MX2012002131A patent/MX339830B/es active IP Right Grant
- 2010-08-18 SG SG10201404970PA patent/SG10201404970PA/en unknown
- 2010-08-18 WO PCT/US2010/045952 patent/WO2011022522A1/en not_active Ceased
- 2010-08-18 PH PH1/2012/500164A patent/PH12012500164A1/en unknown
- 2010-08-18 CN CN201510745347.3A patent/CN105770880A/zh active Pending
- 2010-08-18 JP JP2012525677A patent/JP5947719B2/ja not_active Expired - Fee Related
- 2010-08-18 CA CA2769415A patent/CA2769415A1/en not_active Abandoned
-
2012
- 2012-01-24 IL IL217709A patent/IL217709A/en not_active IP Right Cessation
- 2012-02-21 ZA ZA2012/01286A patent/ZA201201286B/en unknown
-
2016
- 2016-03-03 JP JP2016041230A patent/JP6293181B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-30 US US15/419,523 patent/US20170348405A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6293181B2 (ja) | 免疫原性マラリア原虫周辺スポロゾイトタンパク質エピトープによる組換えアデノウイルスの改変 | |
| JP2013502221A5 (https=) | ||
| US9555089B2 (en) | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes | |
| WO2012023995A1 (en) | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes | |
| JP6097795B2 (ja) | 新規方法および組成物 | |
| JP5222289B2 (ja) | マラリア用ワクチン | |
| EP2160197B1 (en) | Adenoviral vector encoding malaria antigen | |
| US20140294890A1 (en) | Recombinant Adenovirus Vaccines | |
| HU228327B1 (en) | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein | |
| JP2012516679A (ja) | サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用 | |
| McConnell et al. | Characterization of a permissive epitope insertion site in adenovirus hexon | |
| EP3209325A2 (en) | Pfrh5 derived antigen for treatment of malaria | |
| Fonseca et al. | A plasmodium promiscuous T cell epitope delivered within the Ad5 hexon protein enhances the protective efficacy of a protein based malaria vaccine | |
| Bruder et al. | Molecular vaccines for malaria | |
| Palma et al. | Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice | |
| AU2010286187B2 (en) | Modification of recombinant adenovirus with immunogenic Plasmodium circumsporozoite protein epitopes | |
| JP2011505796A (ja) | ワクチン | |
| HK1179508B (en) | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |